LRRK2 Antibody, Clone N231B/34

LRRK2 (Leucine-Rich Repeat Kinase 2) is a large multidomain protein with kinase and GTPase activity, implicated in the pathogenesis of Parkinson’s disease (PD) and other neurodegenerative disorders. Mutations in LRRK2, such as G2019S, are among the most common genetic causes of familial and sporadic PD. LRRK2 regulates vesicle trafficking, autophagy, cytoskeletal dynamics, and immune responses. Its dysregulation leads to mitochondrial dysfunction, impaired lysosomal degradation, and neuroinflammation. LRRK2 is expressed in neurons and glial cells, and its activity is modulated by cellular stress and inflammatory signals. As a central node in neurodegenerative signaling networks, LRRK2 is a high-priority target for disease-modifying therapies in Parkinson’s and related disorders.

LRRK2, Leucine-rich repeat kinase 2, Leucine-rich repeat serine/threonine-protein kinase 2, RIP7, RIPK7, PARK8, Dardarin, ROCO 2, Augmented in rheumatoid arthritis 17

Cytoplasm | Membrane | Mitochondrion | Golgi Apparatus | Cell Projection | Axon | Dendrite | Endoplasmic Reticulum | Cytoplasmic Vesicle | Endosome | Lysosome

Neuroscience | Neurodegeneration | Parkinson's Disease | Cell Signaling | Post-translational Modifications | Phosphorylation | Neuroscience | Neurodegeneration | Multiple System Atrophy

10 µg/ml of SMC-445 was sufficient for detection of LRRK2/Dardarin in 20 µg of rat brain lysate by colorimetric immunoblot analysis using Goat anti-mouse IgG:HRP as the secondary antibody.

Cytoplasm | Membrane | Mitochondrion | Golgi Apparatus | Cell Projection | Axon | Dendrite | Endoplasmic Reticulum | Cytoplasmic Vesicle | Endosome | Lysosome